Literature DB >> 8275936

Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis.

L Rifas1, A Fausto, M J Scott, L V Avioli, H G Welgus.   

Abstract

To more clearly define the expression of metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) within the human osteoblast (hOB) lineage, normal hOB and human osteogenic sarcoma cells possessing various levels of alkaline phosphatase (a marker of commitment to the osteoblast lineage) were treated with bone-resorbing agents to determine their effect on the production of interstitial collagenase, stromelysin, 72-kilodalton (kDa) gelatinase, 92-kDa gelatinase, TIMP-1, and TIMP-2. The results revealed that 1) normal hOB release copious amounts of 72-kDa gelatinase, TIMP-1, and TIMP-2; 2) hOB production of 72-kDa gelatinase and TIMP-2 is not regulated by agents that promote bone resorption (e.g. phorbol-12-myristate 13-acetate, recombinant human interleukin-1 beta, tumor necrosis factor-alpha, PTH, and vitamin D3); 3) normal hOB fail to secrete collagenase, stromelysin, or 92-kDa gelatinase when cultured on plastic or a type I collagen substratum, even in response to bone-resorptive agents or mononuclear cell-conditioned medium; 4) in contrast, certain of the osteogenic sarcoma cell populations produce collagenase, stromelysin, and 92-kDa gelatinase, especially when exposed to bone-resorbing stimuli; 5) in general, the capacity for metalloenzyme production by osteogenic sarcoma cell lines varies inversely with their alkaline phosphatase expression; and 6) the most committed (highest alkaline phosphatase) osteogenic sarcoma cell line, SAOS-2, precisely mimics the metalloproteinase profile of normal hOB. The results suggest that the expression of most metalloproteinases is under strict repression within the differentiated normal hOB, and cellular development is associated with diminished capacity to elaborate such enzymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8275936     DOI: 10.1210/endo.134.1.8275936

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  21 in total

1.  Metabolic activation stimulates acid secretion and expression of matrix degrading proteases in human osteoblasts.

Authors:  M George; B Stein; O Müller; M Weis-Klemm; T Pap; W J Parak; W K Aicher
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

2.  Effects of 17beta-estradiol on the expression of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-2 in human osteoblastic MG-63 cell cultures.

Authors:  E Y Liao; X H Luo; X G Deng; X P Wu
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

3.  Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women.

Authors:  X-H Luo; L-J Guo; P-F Shan; H Xie; X-P Wu; H Zhang; X-Z Cao; L-Q Yuan; E-Y Liao
Journal:  Osteoporos Int       Date:  2005-12-20       Impact factor: 4.507

4.  Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium.

Authors:  Adrian O'Hara; Fei-Ling Lim; Dawn J Mazzatti; Paul Trayhurn
Journal:  Pflugers Arch       Date:  2009-07-09       Impact factor: 3.657

5.  Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis.

Authors:  P Liokumovich; I Goldberg; B Davidson; W H Gotlieb; T Zahavi; G Ben-Baruch; I Reder; J Kopolovic
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

6.  Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.

Authors:  Carrie M Nielson; Jack Wiedrick; Jian Shen; Jon Jacobs; Erin S Baker; Aaron Baraff; Paul Piehowski; Christine G Lee; Arie Baratt; Vladislav Petyuk; Shannon McWeeney; Jeong Youn Lim; Douglas C Bauer; Nancy E Lane; Peggy M Cawthon; Richard D Smith; Jodi Lapidus; Eric S Orwoll
Journal:  J Bone Miner Res       Date:  2017-04-06       Impact factor: 6.741

7.  Osteopenia and decreased bone formation in osteonectin-deficient mice.

Authors:  A M Delany; M Amling; M Priemel; C Howe; R Baron; E Canalis
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

8.  Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type 1-associated dementia.

Authors:  A Ghorpade; R Persidskaia; R Suryadevara; M Che; X J Liu; Y Persidsky; H E Gendelman
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

9.  Exposure to pro-inflammatory cytokines upregulates MMP-9 synthesis by mesenchymal stem cells-derived osteoprogenitors.

Authors:  D Ben David; A Z Reznick; S Srouji; E Livne
Journal:  Histochem Cell Biol       Date:  2008-02-15       Impact factor: 4.304

10.  Membrane-type matrix metalloproteinase-1 (MT1-MMP) is down-regulated in estrogen-deficient rat osteoblast in vivo.

Authors:  E Y Liao; H J Liao; L J Guo; H D Zhou; X P Wu; R C Dai; X H Luo
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.